Application of CD24+ circulating tumor cells in the metastasis and prognosis assessment of neuroblastoma in children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036764

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Interventions

Gold Standard:Pathologic diagnosis

Clinical outcome.

Index test:CD24+&#32

circulating&#32

tumor&#32

cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. For the first time, no surgical treatment or chemotherapy was performed outside the hospital; 2. Residual blood in clinical test > 2ml; 3. No other systemic diseases were associated; 4. Blood samples can be effectively interpreted, without blood clots or hemolysis; 5. Timely follow-up, imaging examination during the follow-up, complete follow-up data; 6. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Other serious systemic diseases; 2. The patient did not receive routine tumor treatment regimen in our hospital.

Design outcomes

Primary

Measure	Time frame
Circulating Tumor Cell Counts;	—

Countries

China

Contacts

Public ContactDong Rui

Children's Hospital of Fudan University

rdong@fudan.edu.cn+86 13524415399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026